Login | English | Deutsch

 Forschungsinformationssystem Universität Greifswald




Originalartikel | erschienen - Druck | peer reviewed | Open Access

Downregulation of interleukin 6 signaling might reduce the risk of periodontitis: a drug target Mendelian randomization study.


Frontiers in Immunology 2023 / Juni ; 14: 1160148 -






Bibliometrische Indikatoren



Impact Factor = 5,7

Zitierhäufigkeit nach WOS = 17

DOI = 10.3389/fimmu.2023.1160148

PubMed-ID = 37342352


Autoren

Nolde M*, Alayash Z, Reckelkamm S, Kocher T1, Ehmke B, Holtfreter B1, Baurecht H, Georgakis M, Baumeister SE


Abstract

Interleukin 6 (IL-6) is considered to play a role in the dysbiotic host response in the development of periodontitis. While the inhibition of the IL-6 receptor using monoclonal antibodies is a well-established therapy for some diseases, so far, its potential benefit in patients with periodontitis has not been examined. We tested the association of genetically proxied downregulation of IL-6 signaling with periodontitis to explore whether downregulation of IL-6 signaling could represent a viable treatment target for periodontitis.

Veröffentlicht in

Frontiers in Immunology


Jahr 2023
Monat/Hj. Juni
Impact Factor (2023) 5,7
Volume 14
Issue
Seiten 1160148 -
Open Access ja
Peer reviewed ja
Artikelart Originalartikel
Artikelstatus erschienen - Druck
DOI 10.3389/fimmu.2023.1160148
PubMed-ID 37342352

Allgemeine Daten zur Fachzeitschrift

Kurzbezeichnung: FRONT IMMUNOL
ISSN: 1664-3224
eISSN: 1664-3224
Land: SWITZERLAND
Sprache: English
Kategorie(n):
  • IMMUNOLOGY


Impact Factor Entwicklung

Jahr Impact Factor
2015 5,695
2016 6,429
2017 5,511
2018 4,716
2019 5,085
2020 7,561
2021 8,786
2022 7,3
2023 5,7
2024 5,9

Themenschwerpunkte


FAQs | Impressum | Datenschutz